Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

By Yahoo! Finance | Nov 8, 2024 at 02:17 AM EST

The company is comfortable with its Q4 guidance but taking a conservative approach due to potential factors like year-end changes. The Enlight Ln registry study is providing insights into lupus treatment patterns, while the company is carefully determining dose levels for AUR200 to balance efficacy and safety.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.